Time to culture conversion and regimen composition in multidrug-resistant tuberculosis treatment

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Tierney, Dylan B ^a,b,j   Franke, Molly F ^b,c,j   Becerra, Mercedes C ^a,b,c,j   Virú, Félix A Alcántara ^b,j   Bonilla, César A ^d   Sánchez, Epifanio ^e   Guerra, Dalia ^b,j   Muñoz, Maribel ^b,j   Llaro, Karim ^b,j   Palacios, Eda ^f   Mestanza, Lorena ^f   Hurtado, Rocío M ^g,h   Furin, Jennifer J ⁱ   Shin, Sonya ^a,b,j   Mitnick, Carole D ^a,b,c,j  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b PARTNERS IN HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MINISTERIO DE SALUD   (Peru)

^e Hospital Nacional Sergio E Bernales   (Peru)

^f Asociacion Visionarios Peru   (Peru)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h Global Health Committee   (United States)

ⁱ CASE WESTERN RESERVE UNIVERSITY   (United States)

^j SOCIOS EN SALUD   (Peru)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EXPOSURE; DRUG SENSITIVITY; DYSPNEA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; PERSONALIZED MEDICINE; RETROSPECTIVE STUDY; SPUTUM CULTURE; SPUTUM CULTURE CONVERSION; TACHYCARDIA; TREATMENT OUTCOME; CLINICAL PROTOCOL; PROPORTIONAL HAZARDS MODEL; TIME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ADULT; ANTITUBERCULAR AGENTS; CLINICAL PROTOCOLS; FEMALE; HUMANS; MALE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TIME FACTORS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84907190320     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108035     Document Type: Article

References (27)

1. World Health Organization (2011) WHO Guidelines Approved by the Guidelines Review Committee. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis: 2011 Update. Geneva: World Health Organization.
2. Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD, et al. (2005) Speaking the same language: treatment outcome definitions for multidrugresistant tuberculosis. Int J Tuberc Lung Dis 9: 640-645.
3. World Health Organization (2010) WHO Guidelines Approved by the Guidelines Review Committee. Treatment of Tuberculosis: Guidelines. Geneva: : World Health Organization.
4. Kurbatova EV, Gammino VM, Bayona J, Becerra M, Danilovitz M, et al. (2011) Frequency and type of microbiological monitoring of multidrug-resistant tuberculosis treatment. Int J Tuberc Lung Dis 15: 1553-1555, i.
5. Qazi F, Khan U, Khowaja S, Javaid M, Ahmed A, et al. (2011) Predictors of delayed culture conversion in patients treated for multidrug-resistant tuberculosis in Pakistan. Int J Tuberc Lung Dis 15: 1556-1559, i.
6. Brust JC, Berman AR, Zalta B, Haramati LB, Ning Y, et al. (2013) Chest radiograph findings and time to culture conversion in patients with multidrugresistant tuberculosis and HIV in Tugela Ferry, South Africa. PLoS One 8: e73975.
7. Kurbatova EV, Gammino VM, Bayona J, Becerra MC, Danilovitz M, et al. (2012) Predictors of sputum culture conversion among patients treated for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 16: 1335-1343.
8. Mitnick CD, Shin SS, Seung KJ, Rich ML, Atwood SS, et al. (2008) Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 359: 563-574.
9. Basit A, Ahmad N, Khan AH, Javaid A, Syed Sulaiman SA, et al. (2014) Predictors of two months culture conversion in multidrug-resistant tuberculosis: findings from a retrospective cohort study. PLoS One 9: e93206.
10. Putri FA, Burhan E, Nawas A, Soepandi PZ, Sutoyo DK, et al. (2014) Body mass index predictive of sputum culture conversion among MDR-TB patients in Indonesia. The International Journal of Tuberculosis and Lung Disease 18: 564-570.
11. Magee MJ, Kempker RR, Kipiani M, Tukvadze N, Howards PP, et al. (2014) Diabetes mellitus, smoking status, and rate of sputum culture conversion in patients with multidrug-resistant tuberculosis: a cohort study from the country of georgia. PLoS One 9: e94890.
12. Lienhardt C, Davies G (2010) Methodological issues in the design of clinical trials for the treatment of multidrug-resistant tuberculosis: challenges and opportunities. Int J Tuberc Lung Dis 14: 528-537.
13. Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, et al. (2012) Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 366: 2151-2160.
14. Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, et al. (2009) The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 360: 2397-2405.
15. Mitnick CD, Franke MF, Rich ML, Alcantara Viru FA, Appleton SC, et al. (2013) Aggressive regimens for multidrug-resistant tuberculosis decrease allcause mortality. PLoS One 8: e58664.
16. Mukherjee JS, Rich ML, Socci AR, Joseph JK, Viru FA, et al. (2004) Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 363: 474-481.
17. Rouillon A, Perdrizet S, Parrot R (1976) Transmission of tubercle bacilli: The effects of chemotherapy. Tubercle 57: 275-299.
18. Therneau TM (1996) Extending the Cox Model. Technical Report 56, Section of Biostatistics, Mayo Clinic, Rochester. Available: http://www.mayo.edu/hsr/techrpt/58.pdf. Accessed 12 August 2014.
19. Therneau TM, Grambsch PM (2000) Modeling Survival Data: Extending the Cox Model. New York: Springer - Verlag. 350 p.
20. Johnson JL, Vjecha MJ, Okwera A, Hatanga E, Byekwaso F, et al. (1998) Impact of human immunodeficiency virus type-1 infection on the initial bacteriologic and radiographic manifestations of pulmonary tuberculosis in Uganda. Makerere University-Case Western Reserve University Research Collaboration. Int J Tuberc Lung Dis 2: 397-404.
21. Visser ME, Stead MC, Walzl G, Warren R, Schomaker M, et al. (2012) Baseline predictors of sputum culture conversion in pulmonary tuberculosis: importance of cavities, smoking, time to detection and W-Beijing genotype. PLoS One 7: e29588.
22. Brust JC, Lygizos M, Chaiyachati K, Scott M, van der Merwe TL, et al. (2011) Culture conversion among HIV co-infected multidrug-resistant tuberculosis patients in Tugela Ferry, South Africa. PLoS One 6: e15841.
23. Wallis RS (2013) Sustainable tuberculosis drug development. Clin Infect Dis 56: 106-113.
24. Avorn J (2013) Approval of a tuberculosis drug based on a paradoxical surrogate measure. JAMA 309: 1349-1350.
25. Burman WJ (2010) Rip Van Winkle wakes up: development of tuberculosis treatment in the 21st century. Clin Infect Dis 50 Suppl 3: S165-172.
26. Velasquez GE, Becerra MC, Gelmanova IY, Pasechnikov AD, Yedilbayev A, et al. (2014) Improving outcomes for multidrug-resistant tuberculosis: Aggressive regimens prevent treatment failure and death. Clin Infect Dis. May 7 [Epub ahead of print].
27. Franke MF, Appleton SC, Mitnick CD, Furin JJ, Bayona J, et al. (2013) Aggressive regimens for multidrug-resistant tuberculosis reduce recurrence. Clin Infect Dis 56: 770-776.